Sanofi Pasteur Developed Dengvaxia: The First Vaccine For The Prevention Of Dengue

The Federal Commission for the Protection Against Sanitary Risks (COFEPRIS) has approved a new vaccine that would reduce the risk of dengue on children. Dengvaxia, the tetravalent dengue vaccine is the first vaccine that is certified in the world for the inhibition of the dengue disease. 

Dengue is a disease that can cause serious illness and death not only on children but with adults as well. Although dengue born mosquitoes can be found all over the world, it is mostly prevalent in Latin American and Asian Countries, BABW NEWS reported. 

The new vaccine is developed by Sanofi Pasteur and was approved in Mexico. Its main task is to aid in preventing the disease that is caused by four dengue virus types namely the DEN-1, DEN-2, DEN-3, and DEN-4. The four types have various interactions with the antibodies in the human blood serum and have genetic variations. However, even though they have variations, they have the same range of clinical symptoms such as high fever, pain behind the eyes, nausea, severe headaches, fatigue, severe joint and muscle pain, skin rash and vomiting.

The World Health Organization website referred to dengue as hemorrhagic fever is a mosquito-borne disease that is conveyed by the infective bite of a mosquito. The disease mostly affects young children and adults and can occur after 3 to 14 days after the infected mosquito bite.

The WHO also stated that there is no particular treatment for dengue fever. Patients must rest and drink plenty of water. The fever may only be reduced by the paracetamol prescribed by doctors.

The World Health Organization estimated that there may be 50 to 100 million dengue infections all over the world annually. And about 500,000 children were affected. The organization also appeals for the development of dengue vaccine to lower the rate of dengue all around the world. The outcome shows that if you vaccinate 20 percent of the population in 10 prevalent countries that joined the three phases of the clinical development program for a vaccine, in the ages 9 and 45 years old, there would be a reduction of dengue for about 50 percent in 5 years.

Meanwhile, the approval of Dengvaxia is centered on the outcome from a broad clinical development program that involves 40,000 people in 15 countries. Sanofi Pasteur has started working with the vaccine about 20 years ago.

The processes for Dengvaxia have been reviewed by regulatory in some endemic countries. Meanwhile, its manufacturing has already started in France. Sanofi Pasteur also prioritizes the introduction of Dengvaxia to countries that are most affected by dengue infections.